Cargando…
Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells
The aim of the present study was to examine the multi-targeted potential of a monoclonal antibody against mucin-1 (MUC1) and novel octahydropyrazin[2,1-a:5,4-a′]diisoquinoline derivative (OM-86II) in estrogen receptor-positive MCF-7 human breast cancer cells. The cell viability was measured by an MT...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718100/ https://www.ncbi.nlm.nih.gov/pubmed/31524251 http://dx.doi.org/10.3892/or.2019.7256 |
_version_ | 1783447681380646912 |
---|---|
author | Gornowicz, Agnieszka Szymanowski, Wojciech Bielawska, Anna Szymanowska, Anna Czarnomysy, Robert Kałuża, Zbigniew Bielawski, Krzysztof |
author_facet | Gornowicz, Agnieszka Szymanowski, Wojciech Bielawska, Anna Szymanowska, Anna Czarnomysy, Robert Kałuża, Zbigniew Bielawski, Krzysztof |
author_sort | Gornowicz, Agnieszka |
collection | PubMed |
description | The aim of the present study was to examine the multi-targeted potential of a monoclonal antibody against mucin-1 (MUC1) and novel octahydropyrazin[2,1-a:5,4-a′]diisoquinoline derivative (OM-86II) in estrogen receptor-positive MCF-7 human breast cancer cells. The cell viability was measured by an MTT assay. The analyses of cell cycle and disruption of mitochondrial membrane potential were performed by flow cytometry. Fluorescent microscopy and flow cytometry were used to demonstrate the effect of the compounds on apoptosis. ELISA was conducted to check the concentrations of proteins involved in multiple intracellular signaling pathways, responsible for the promotion of tumor growth and breast cancer progression, namely matrix metalloproteinase (MMP)-2, matrix MMP-9, tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), soluble intercellular adhesion molecule 1 (sICAM1) and mTOR. The combination therapy based on anti-MUC1 antibody and novel OM-86II inhibited the proliferation of MCF-7 breast cancer cells. Its inhibitory effects were associated with the induction of cell cycle arrest and apoptosis. It was demonstrated that anti-MUC1 antibody with OM-86II decreased the concentrations of MMP-2, MMP-9, sICAM1 and mTOR. In addition, the combined therapy exhibited anti-inflammatory activity, which was demonstrated by a decrease in TNF-α and COX-2 concentrations. The present data provided evidence that the combination of anti-MUC1 antibody with novel OM-86II represents a multi-targeted strategy in MCF-7 breast cancer treatment. |
format | Online Article Text |
id | pubmed-6718100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-67181002019-09-04 Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells Gornowicz, Agnieszka Szymanowski, Wojciech Bielawska, Anna Szymanowska, Anna Czarnomysy, Robert Kałuża, Zbigniew Bielawski, Krzysztof Oncol Rep Articles The aim of the present study was to examine the multi-targeted potential of a monoclonal antibody against mucin-1 (MUC1) and novel octahydropyrazin[2,1-a:5,4-a′]diisoquinoline derivative (OM-86II) in estrogen receptor-positive MCF-7 human breast cancer cells. The cell viability was measured by an MTT assay. The analyses of cell cycle and disruption of mitochondrial membrane potential were performed by flow cytometry. Fluorescent microscopy and flow cytometry were used to demonstrate the effect of the compounds on apoptosis. ELISA was conducted to check the concentrations of proteins involved in multiple intracellular signaling pathways, responsible for the promotion of tumor growth and breast cancer progression, namely matrix metalloproteinase (MMP)-2, matrix MMP-9, tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), soluble intercellular adhesion molecule 1 (sICAM1) and mTOR. The combination therapy based on anti-MUC1 antibody and novel OM-86II inhibited the proliferation of MCF-7 breast cancer cells. Its inhibitory effects were associated with the induction of cell cycle arrest and apoptosis. It was demonstrated that anti-MUC1 antibody with OM-86II decreased the concentrations of MMP-2, MMP-9, sICAM1 and mTOR. In addition, the combined therapy exhibited anti-inflammatory activity, which was demonstrated by a decrease in TNF-α and COX-2 concentrations. The present data provided evidence that the combination of anti-MUC1 antibody with novel OM-86II represents a multi-targeted strategy in MCF-7 breast cancer treatment. D.A. Spandidos 2019-10 2019-08-02 /pmc/articles/PMC6718100/ /pubmed/31524251 http://dx.doi.org/10.3892/or.2019.7256 Text en Copyright: © Gornowicz et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Gornowicz, Agnieszka Szymanowski, Wojciech Bielawska, Anna Szymanowska, Anna Czarnomysy, Robert Kałuża, Zbigniew Bielawski, Krzysztof Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells |
title | Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells |
title_full | Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells |
title_fullStr | Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells |
title_full_unstemmed | Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells |
title_short | Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells |
title_sort | monoclonal anti-muc1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in mcf-7 breast cancer cells |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718100/ https://www.ncbi.nlm.nih.gov/pubmed/31524251 http://dx.doi.org/10.3892/or.2019.7256 |
work_keys_str_mv | AT gornowiczagnieszka monoclonalantimuc1antibodywithnoveloctahydropyrazino21a54adiisoquinolinederivativeasapotentialmultitargetedstrategyinmcf7breastcancercells AT szymanowskiwojciech monoclonalantimuc1antibodywithnoveloctahydropyrazino21a54adiisoquinolinederivativeasapotentialmultitargetedstrategyinmcf7breastcancercells AT bielawskaanna monoclonalantimuc1antibodywithnoveloctahydropyrazino21a54adiisoquinolinederivativeasapotentialmultitargetedstrategyinmcf7breastcancercells AT szymanowskaanna monoclonalantimuc1antibodywithnoveloctahydropyrazino21a54adiisoquinolinederivativeasapotentialmultitargetedstrategyinmcf7breastcancercells AT czarnomysyrobert monoclonalantimuc1antibodywithnoveloctahydropyrazino21a54adiisoquinolinederivativeasapotentialmultitargetedstrategyinmcf7breastcancercells AT kałuzazbigniew monoclonalantimuc1antibodywithnoveloctahydropyrazino21a54adiisoquinolinederivativeasapotentialmultitargetedstrategyinmcf7breastcancercells AT bielawskikrzysztof monoclonalantimuc1antibodywithnoveloctahydropyrazino21a54adiisoquinolinederivativeasapotentialmultitargetedstrategyinmcf7breastcancercells |